MedTrace Logo

Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)

NCT00380705 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2024-08-15

No results posted yet for this study

Summary

Allow physicians not familiar with anti-leukotriene based therapy to test it

Conditions

Interventions

DRUG

MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-18
Primary Completion
2005-07-29
Completion
2005-07-29

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00380705 on ClinicalTrials.gov